To enact section 124.826 of the Revised Code regarding reimbursements to state employees and elected state officials for GLP-1 drug costs.
Summary
HB388 would create a new section of the Revised Code requiring the state employee health benefits program to reimburse certain out-of-pocket costs for GLP-1 drugs used for chronic weight management. The reimbursement would be available to state employees and elected state officials who meet specified conditions, including a physician-determined body mass index of at least 30 at treatment initiation, purchase of a non-compounded GLP-1 drug approved by the FDA for chronic weight management, and use of a manufacturer direct-to-consumer program or participating pharmacy/entity.
The bill sets a reimbursement structure that generally lasts up to 24 consecutive months, with a possible later renewal period if the person regains at least 20% of the weight lost during the prior period. During the first year, reimbursement would be capped at $500 per month; during the second year, it would be limited to one-half of the out-of-pocket cost, up to $250 per month. The director of administrative services would administer the program and adopt rules to implement it.
Impact
HB388 would expand the state employee health care benefits under section 124.82 of the Revised Code by mandating reimbursement for qualifying GLP-1 weight-loss medications, notwithstanding other conflicting provisions of state law. It would create new eligibility, documentation, and reimbursement rules for the Department of Administrative Services, while also limiting the benefit to FDA-approved chronic weight management drugs and excluding compounded versions. The bill would directly affect state employees and elected state officials who seek coverage for these medications, and it would likely increase state benefit costs and administrative oversight obligations.
Sentiment
The bill appears to be narrowly targeted and policy-driven, with no recorded committee testimony or votes available in the provided materials. Based on the text, it is framed as a health benefits expansion for state workers and officials rather than a broad public program, suggesting a practical rather than ideological approach. Because there is no recorded debate in the supplied context, the overall sentiment cannot be measured from committee discussion, but the introduced language indicates an intent to support access to weight-management treatment under controlled conditions.
Contention
The main points of contention likely involve cost, fairness, and medical eligibility standards. Critics may question whether state funds should reimburse expensive GLP-1 drugs for employees and elected officials, especially when the benefit is limited to a specific class of medications and tied to weight-loss treatment. Supporters may argue the bill promotes access to clinically recognized obesity treatment and includes safeguards such as BMI thresholds, physician verification, time limits, and exclusions for compounded drugs. The renewal provision based on regained weight could also be controversial because it creates a second eligibility pathway tied to prior weight-loss outcomes.